The effect of human bone marrow stromal cells and dermal fibroblasts on angiogenesis

Seung-Kyu Han, Kyung Wook Chun, Min Seok Gye, Woo-Kyung Kim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: A cell therapy methodology for angiogenesis using fibroblasts has already been developed. Bone marrow stromal cells, which contain mesenchymal stem cells, have a low rate of immunity-assisted rejection and are capable of expanding profoundly in culture. Therefore, these cells offer several advantages for transplantation over mature cells. The aim of this study was to compare the angiogenic activity of bone marrow stromal cells with that of fibroblasts. METHODS: For in vitro study, cultured human bone marrow stromal cells and dermal fibroblasts were seeded onto 96-well culture plates. After 1, 3, and 5 days, the levels of the basic fibroblast growth factor and vascular endothelial growth factor were compared. For in vivo study, porous polyethylene disks were loaded with bone marrow stromal cells, fibroblasts, or no cells and then implanted in the backs of rats. At three time intervals ranging from 1 to 3 weeks, the microvascular density was measured. RESULTS: In the in vitro study, the basic fibroblast growth factor levels in the bone marrow stromal cell group were 47, 89, and 68 percent higher than in the fibroblast group at each time interval (p < 0.05). The vascular endothelial growth factor levels of the bone marrow stromal cell group were seven, 12, and 12 times higher than those of the fibroblast group (p < 0.05). In the in vivo study, there was little difference in the microvascular density among the three groups by the second week. However, the 3-week specimens showed a significantly greater difference. The microvascular density averaged 52.88, 26.12, and 17.50 for the bone marrow stromal cell, fibroblast, and no-cell groups, respectively. CONCLUSION: These results suggest that bone marrow stromal cells may possibly be used as a replacement for fibroblasts for angiogenesis.

Original languageEnglish
Pages (from-to)829-835
Number of pages7
JournalPlastic and Reconstructive Surgery
Volume117
Issue number3
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

Mesenchymal Stromal Cells
Fibroblasts
Skin
Fibroblast Growth Factor 2
Vascular Endothelial Growth Factor A
Polyethylene
Cell- and Tissue-Based Therapy
Immunity
Transplantation

ASJC Scopus subject areas

  • Surgery

Cite this

The effect of human bone marrow stromal cells and dermal fibroblasts on angiogenesis. / Han, Seung-Kyu; Chun, Kyung Wook; Gye, Min Seok; Kim, Woo-Kyung.

In: Plastic and Reconstructive Surgery, Vol. 117, No. 3, 01.03.2006, p. 829-835.

Research output: Contribution to journalArticle

Han, Seung-Kyu ; Chun, Kyung Wook ; Gye, Min Seok ; Kim, Woo-Kyung. / The effect of human bone marrow stromal cells and dermal fibroblasts on angiogenesis. In: Plastic and Reconstructive Surgery. 2006 ; Vol. 117, No. 3. pp. 829-835.
@article{bbafef6389ec466c8b6aa9221c9b33fc,
title = "The effect of human bone marrow stromal cells and dermal fibroblasts on angiogenesis",
abstract = "BACKGROUND: A cell therapy methodology for angiogenesis using fibroblasts has already been developed. Bone marrow stromal cells, which contain mesenchymal stem cells, have a low rate of immunity-assisted rejection and are capable of expanding profoundly in culture. Therefore, these cells offer several advantages for transplantation over mature cells. The aim of this study was to compare the angiogenic activity of bone marrow stromal cells with that of fibroblasts. METHODS: For in vitro study, cultured human bone marrow stromal cells and dermal fibroblasts were seeded onto 96-well culture plates. After 1, 3, and 5 days, the levels of the basic fibroblast growth factor and vascular endothelial growth factor were compared. For in vivo study, porous polyethylene disks were loaded with bone marrow stromal cells, fibroblasts, or no cells and then implanted in the backs of rats. At three time intervals ranging from 1 to 3 weeks, the microvascular density was measured. RESULTS: In the in vitro study, the basic fibroblast growth factor levels in the bone marrow stromal cell group were 47, 89, and 68 percent higher than in the fibroblast group at each time interval (p < 0.05). The vascular endothelial growth factor levels of the bone marrow stromal cell group were seven, 12, and 12 times higher than those of the fibroblast group (p < 0.05). In the in vivo study, there was little difference in the microvascular density among the three groups by the second week. However, the 3-week specimens showed a significantly greater difference. The microvascular density averaged 52.88, 26.12, and 17.50 for the bone marrow stromal cell, fibroblast, and no-cell groups, respectively. CONCLUSION: These results suggest that bone marrow stromal cells may possibly be used as a replacement for fibroblasts for angiogenesis.",
author = "Seung-Kyu Han and Chun, {Kyung Wook} and Gye, {Min Seok} and Woo-Kyung Kim",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.prs.0000201458.80364.31",
language = "English",
volume = "117",
pages = "829--835",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The effect of human bone marrow stromal cells and dermal fibroblasts on angiogenesis

AU - Han, Seung-Kyu

AU - Chun, Kyung Wook

AU - Gye, Min Seok

AU - Kim, Woo-Kyung

PY - 2006/3/1

Y1 - 2006/3/1

N2 - BACKGROUND: A cell therapy methodology for angiogenesis using fibroblasts has already been developed. Bone marrow stromal cells, which contain mesenchymal stem cells, have a low rate of immunity-assisted rejection and are capable of expanding profoundly in culture. Therefore, these cells offer several advantages for transplantation over mature cells. The aim of this study was to compare the angiogenic activity of bone marrow stromal cells with that of fibroblasts. METHODS: For in vitro study, cultured human bone marrow stromal cells and dermal fibroblasts were seeded onto 96-well culture plates. After 1, 3, and 5 days, the levels of the basic fibroblast growth factor and vascular endothelial growth factor were compared. For in vivo study, porous polyethylene disks were loaded with bone marrow stromal cells, fibroblasts, or no cells and then implanted in the backs of rats. At three time intervals ranging from 1 to 3 weeks, the microvascular density was measured. RESULTS: In the in vitro study, the basic fibroblast growth factor levels in the bone marrow stromal cell group were 47, 89, and 68 percent higher than in the fibroblast group at each time interval (p < 0.05). The vascular endothelial growth factor levels of the bone marrow stromal cell group were seven, 12, and 12 times higher than those of the fibroblast group (p < 0.05). In the in vivo study, there was little difference in the microvascular density among the three groups by the second week. However, the 3-week specimens showed a significantly greater difference. The microvascular density averaged 52.88, 26.12, and 17.50 for the bone marrow stromal cell, fibroblast, and no-cell groups, respectively. CONCLUSION: These results suggest that bone marrow stromal cells may possibly be used as a replacement for fibroblasts for angiogenesis.

AB - BACKGROUND: A cell therapy methodology for angiogenesis using fibroblasts has already been developed. Bone marrow stromal cells, which contain mesenchymal stem cells, have a low rate of immunity-assisted rejection and are capable of expanding profoundly in culture. Therefore, these cells offer several advantages for transplantation over mature cells. The aim of this study was to compare the angiogenic activity of bone marrow stromal cells with that of fibroblasts. METHODS: For in vitro study, cultured human bone marrow stromal cells and dermal fibroblasts were seeded onto 96-well culture plates. After 1, 3, and 5 days, the levels of the basic fibroblast growth factor and vascular endothelial growth factor were compared. For in vivo study, porous polyethylene disks were loaded with bone marrow stromal cells, fibroblasts, or no cells and then implanted in the backs of rats. At three time intervals ranging from 1 to 3 weeks, the microvascular density was measured. RESULTS: In the in vitro study, the basic fibroblast growth factor levels in the bone marrow stromal cell group were 47, 89, and 68 percent higher than in the fibroblast group at each time interval (p < 0.05). The vascular endothelial growth factor levels of the bone marrow stromal cell group were seven, 12, and 12 times higher than those of the fibroblast group (p < 0.05). In the in vivo study, there was little difference in the microvascular density among the three groups by the second week. However, the 3-week specimens showed a significantly greater difference. The microvascular density averaged 52.88, 26.12, and 17.50 for the bone marrow stromal cell, fibroblast, and no-cell groups, respectively. CONCLUSION: These results suggest that bone marrow stromal cells may possibly be used as a replacement for fibroblasts for angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=33645745788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645745788&partnerID=8YFLogxK

U2 - 10.1097/01.prs.0000201458.80364.31

DO - 10.1097/01.prs.0000201458.80364.31

M3 - Article

VL - 117

SP - 829

EP - 835

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 3

ER -